8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
Abbott reports 14.5% third-quarter sales growth, reaffirms 2026 EPS outlook
Filed with the SEC on · Summarized by InvestorsBot
Abbott reported third-quarter 2026 sales of $13.013 billion for the period ended September 30, up 14.5% from a year earlier, while comparable sales rose 7.0%; GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.42. The company reaffirmed approximately 6.0% full-year comparable sales growth and narrowed its adjusted diluted EPS guidance to $5.50-$5.55, with growth supported by Diagnostics, including Exact Sciences, and Medical Devices; Abbott also declared a quarterly dividend of $0.63 per share payable November 16, 2026.